California Institute for Quantitative Biosciences

Capsida Biotherapeutics Presents Data Demonstrating Unique Industry-Leading Technology and Capabilities With Potential to Treat Both Rare and Common Diseases at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Wednesday, May 18, 2022
Engineering, Company, Annual general meeting, Capsid, HEK 293 cells, Washington Convention Center, Multimedia, AbbVie, Automation, HEK293, Translation, Liver, Society, Research, Patent, Gene, Efficiency, CNS, Brain, Spinal cord, California Institute for Quantitative Biosciences, AAV, Kaay Raav Tumhi, Intellectual property, Biotechnology, CRISPR, Walter, Central nervous system, Walter E. Washington Convention Center, Therapy, Cell, Transfection, Bioreactor, Tissue, Vaccine, Mobile phone, Technology

THOUSAND OAKS, Calif., May 18, 2022 /PRNewswire/ -- Capsida Biotherapeutics ("Capsida"), the only fully integrated gene therapy platform company that through intravenous (IV) delivery of a single, engineered capsid can target single or multiple organs simultaneously while limiting exposure to non-targeted organs, today announced four posters delivered at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. Capsida's approach unlocks the potential to treat both rare and common diseases across all ages.

Key Points: 
  • Capsida's approach unlocks the potential to treat both rare and common diseases across all ages.
  • The ASGCT Annual Meeting is being held virtually and in person May 16-19, 2022, in Washington, D.C. at the Walter E. Washington Convention Center.
  • The totality of these data, along with achievements in our process development and manufacturing processes, will allow us to rapidly advance gene therapies into the clinic."
  • The company is exploring using the technology across a broad range of rare and more common genetic and sporadic disorders.

X-Therma Receives FDA Breakthrough Device Designation for XT-ViVo® Preservation Solution and TimeSeal® Organ Transport Device

Retrieved on: 
Tuesday, May 3, 2022
Medical Devices, Surgery, Medical Supplies, Hospitals, FDA, Genetics, Other Health, Biotechnology, General Health, Health, California Institute for Regenerative Medicine, Ischemia, Regenerative medicine, Transplant, Breakthrough, CTO, Kidney, Food, U.S. Department of Defense Strategy for Operating in Cyberspace, Food and Drug Administration, FDA Center for Devices and Radiological Health, Patient, San Francisco Bay Area, Perfusion, Device, National Science Foundation, Program, FDA, Diagnosis, Industry, CDRH, Adult, Lawrence Berkeley National Laboratory, Center, Vaccine, Intention, California Institute for Quantitative Biosciences, CEO, Technology, Transport, Pharmaceutical industry, Dentistry, Medical device

X-Therma Inc. , a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - announced today that The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has granted its proprietary organ preservation solution, XT-ViVo, and TimeSeal Organ Transport Device, Breakthrough Device status.

Key Points: 
  • X-Therma Inc. , a biotechnology company developing breakthrough technology for regenerative medicine and organ preservation - announced today that The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has granted its proprietary organ preservation solution, XT-ViVo, and TimeSeal Organ Transport Device, Breakthrough Device status.
  • XT-ViVo is a novel organ preservation solution indicated for perfusion and flushing of a donor's kidney prior to removal from the donor or immediately after removal from the donor.
  • The solution is left in the organ vasculature during hypothermic storage and transportation to the recipient.
  • TimeSeal Organ Transport Device is designed for static hypothermic preservation of adult donor kidneys during transportation and subsequent transplantation into a recipient using XT-ViVo.

Amorphology Partners with AddiTec for the Additive Manufacturing of Multi-Metal Robotics Gear Components

Retrieved on: 
Friday, April 29, 2022
JPL, DED, BMG, California Institute of Technology, Business development, Mining, Fatigue, Jet Propulsion Laboratory, Metal, Diffusion, Partnership, University, Intellectual property, NASA, California Institute for Quantitative Biosciences, Powder, Ecosystem, Robotics, Hardness, Rb, Printing, 3D, Steel, 3D printing, Technology

Together, Amorphology and AddiTec are developing the additive manufacturing of multi-metal gear components for robotics.

Key Points: 
  • Together, Amorphology and AddiTec are developing the additive manufacturing of multi-metal gear components for robotics.
  • "Functional grading with multiple materials allows us to develop gear components for robotics that cannot be fabricated with conventional metallurgy.
  • For large gears where it makes sense to use additive manufacturing to save machining costs, this could be a real advantage."
  • Amorphology is a leader in applying advanced materials and manufacturing technologies toward improving gear production for robotics and other industrial applications using amorphous metals, also known as bulk metal glass (BMG), additive manufacturing, and custom metal alloys and composites.

Immune-Onc Therapeutics to Participate in the Raymond James LILRB/ILT Symposium on Myeloid Checkpoint Therapeutics in Cancer

Retrieved on: 
Tuesday, April 19, 2022
Pharmaceutical, Genetics, Health, Oncology, LILRB2, Drug development, Physiology, CIRM, Biotechnology, California Institute for Quantitative Biosciences, Raymond James Financial, NIH, National Cancer Institute, Leukemia, LILRB4, Leukemia & Lymphoma Society, Twitter, Memorial Sloan Kettering Cancer Center, University, LLS, Research, CMML, Immunotherapy, Food, White blood cell, ILT4, Chronic myelomonocytic leukemia, Regulation of tobacco by the U.S. Food and Drug Administration, LAIR1, National, Patient, LinkedIn, University of Texas at Austin, Company, Albert Einstein College of Medicine, ILT3, Lymphatic system, AML, Regenerative medicine, Tumor microenvironment, Biology, NCI, Record, University of Texas Southwestern Medical Center, Acute myeloid leukemia, California Institute for Regenerative Medicine, Therapy, Vaccine, Cancer

Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022, at 2:00 PM EDT, hosted by Raymond James biotech analysts.

Key Points: 
  • Immune-Onc Therapeutics, Inc. (Immune-Onc), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced the Company will present at the virtual LILRB/ILT Symposium: A Deep Dive into Myeloid Checkpoint Therapeutics in Cancer on Tuesday, April 26, 2022, at 2:00 PM EDT, hosted by Raymond James biotech analysts.
  • As a private company and a leader in LILRB/ILT family of myeloid checkpoint target validation and therapeutics development, we are pleased to be invited to the Raymond James LILRB/ILT Symposium, said Charlene Liao, Ph.D., chief executive officer of Immune-Onc.
  • Immune-Onc was founded on groundbreaking science that first illuminated the role of the previously unexplored LILRB family of myeloid checkpoints in cancer.
  • Immune-Onc Therapeutics, Inc. (Immune-Onc) is a private, clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients.

Neuvivo Announces Addition of Michael Snyder, PhD - Chair of the Department of Genetics at the Stanford School of Medicine - to Scientific Advisory Board

Retrieved on: 
Thursday, April 14, 2022
ALS, CEO, Biology, German Resource Center for Genome Research, Macrophage, Biotechnology, California Institute for Quantitative Biosciences, Prognosis, Postdoctoral researcher, Stanford University, Developmental Biology (journal), Hisba, Coronavirus Scientific Advisory Board (Turkey), Chemistry, Center, Yale University, Snyder, Central nervous system, Doctor of Philosophy, Patient, Stanford University School of Medicine, CSO, Genome, Health, Immune system, University of Rochester, CT, Secondary research, Method, Neurodegeneration, Personalized medicine, Gene, PALO, De novo, RNA-Seq, Life Technologies, University, IPOP, Proteomics, Medical device, Technology, Illumina, Genomics, Genetics, Philip H. Mirvis

PALO ALTO, Calif., April 14, 2022 /PRNewswire/ -- Neuvivo today announced that Michael Snyder, PhD, will join the company's Scientific Advisory Board. Dr. Snyder is one of the world's leading experts in genetics and is credited with advancing the fields of functional genomics, personalized medicine and proteomics. Since 2009 Dr. Snyder has been the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine, Stanford University School of Medicine. His lab is recognized as the first to perform a large-scale functional genomics project in any organism and he is recognized for combining novel "omics" technologies to perform the first-ever longitudinal integrative personal omics profile (iPOP) of people to assess disease risk and monitor disease states for personalized medicine.

Key Points: 
  • PALO ALTO, Calif., April 14, 2022 /PRNewswire/ -- Neuvivo today announced that Michael Snyder, PhD, will join the company's Scientific Advisory Board.
  • Dr. Snyder is one of the world's leading experts in genetics and is credited with advancing the fields of functional genomics, personalized medicine and proteomics.
  • Since 2009 Dr. Snyder has been the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine, Stanford University School of Medicine.
  • He did Postdoctoral Research at the Stanford University School of Medicine under Dr. Ronald Davis.

Virtualitics meets SOC2 info security standards in all 40 categories

Retrieved on: 
Thursday, April 7, 2022
Risk, Organization, American Institute, NASA, CPAS, Compliance, Research, SOC, Confidentiality, California Institute for Quantitative Biosciences, Review, SOC 2, Awareness, Jet Propulsion Laboratory, AI, Technology, Medical device

PASADENA, Calif., April 7, 2022 /PRNewswire/ -- Today, Virtualitics Inc, an advanced analytics and predictive AI company, announced that it has successfully completed the SOC 2 audit. The third-party audit shows the company meets rigorous cybersecurity standards in all 40 categories examined. The review included cyberattack prevention, insider risk, network management, staff hiring and training, and much more.

Key Points: 
  • The third-party audit shows the company meets rigorous cybersecurity standards in all 40 categories examined.
  • "It's unusual for a startup company to make SOC2 an early priorityit's typically a maturity process" notes Virtualitics' Chief Information Security Officer, Alfred Valerio.
  • It should give our clients high confidence in how well we're protecting their data on our Virtualitics AI Platform."
  • SOC2 Type II Report is a security framework developed by the American Institute of CPAs to assess a company's level of risk from cyber threats.

 Affini-T Expands Board of Directors with Appointments of Michael Varney, Ph.D., and Daniel Faga

Retrieved on: 
Tuesday, April 5, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Drug development, Mace Head Atmospheric Research Station, Therapy, University, LinkedIn, Cornell University, Wharton School of the University of Pennsylvania, Â, University of California, San Francisco, Synthetic biology, Genentech, Growth, Patient, Interline, KRAS, Biotechnology, Cancer, Centerview Partners, Roche, Observer, California Institute for Quantitative Biosciences, Acquisition, Twitter, Doctor of Philosophy, MBA, Chemistry, Drug discovery, Spark Therapeutics, Engineering, Medical imaging, Management, Research, Technology

Affini-T Therapeutics, Inc , a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointments of Michael Varney, Ph.D., and Daniel Faga to its board of directors.

Key Points: 
  • Affini-T Therapeutics, Inc , a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced the appointments of Michael Varney, Ph.D., and Daniel Faga to its board of directors.
  • Dr. Varney and Mr. Faga join a powerhouse of industry leaders across biotechnology, venture capital, drug development and cell and gene therapy on Affini-Ts board including Directors Jak Knowles, M.D.
  • , Arjun Goyal, M.D., M.Phil ., and Lucio Iannone, Ph.D. , along with Observers Sebastin Bernales, Ph.D. , Rakhshita Dhar and Sean Parker .
  • He is currently the Chair of R&D, Scientific Advisory Board Member and Board Director at Erasca, and Board Director of Pardes Biosciences, Interline Therapeutics and Atomwise.

Scorpion Therapeutics Appoints Saurabh Saha, M.D., Ph.D. to its Board of Directors

Retrieved on: 
Monday, April 4, 2022
Oncology, Health, General Health, Research, Pharmaceutical, Science, Drug development, Therapy, Company, McKinsey & Company, Sale, Leadership, University, Norwest Venture Partners, Board, Biophysics, Novartis, Cancer, Celgene, Precision medicine, Johns Hopkins School of Medicine, Scorpion, Board of directors, Precision, California Institute for Quantitative Biosciences, Member, AbbVie, Acquisition, Nasdaq, Harvard Medical School, Harvard Business School, CNTA, Efficiency, Research and development, Atlas Venture, Patient, Management, Pharmaceutical industry, Biochemistry, Technology

Scorpion Therapeutics, Inc. (Scorpion Therapeutics), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors.

Key Points: 
  • Scorpion Therapeutics, Inc. (Scorpion Therapeutics), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the appointment of Saurabh Saha, M.D., Ph.D. to its Board of Directors.
  • We are pleased to welcome Dr. Saha to our Board of Directors, said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics.
  • Im incredibly excited to work alongside my fellow Board members and the executive team to advance the next frontier of precision medicines, said Dr. Saha.
  • Scorpion Therapeutics is a pioneering oncology company redefining the frontier of precision medicine to deliver optimized and transformational therapies for larger populations of patients with cancer, a strategy Scorpion Therapeutics refers to as Precision Oncology 2.0.

Virtualitics AI Platform to Support Computational Biology Research on Long Covid Treatment Options

Retrieved on: 
Wednesday, March 30, 2022
Organization, Institute for Systems Biology, NASA, Diagnosis, Risk, Research, CSO, Systems biology, Genomics, Data analysis, CEO, California Institute for Quantitative Biosciences, Cell, Institute, COVID-19, Long COVID, Jet Propulsion Laboratory, AI, Technology, Proteomics, Patient, ISB, Pharmaceutical industry, Medical device

PASADENA, Calif., March 30, 2022 /PRNewswire/ -- Today, Virtualitics Inc, an advanced analytics and predictive AI company announced that the Institute for Systems Biology (ISB) will employ Virtualitics' AI platform to enable researchers to discover the connections between vast amounts of Covid-related data for a research study on Long Covid treatment options. The research builds on a recent Long Covid study by ISB published in the journal Cell that uncovered four risk factors, measured before or at COVID-19 diagnosis, that identify which patients are likely to develop Long Covid.

Key Points: 
  • PASADENA, Calif., March 30, 2022 /PRNewswire/ -- Today, Virtualitics Inc, an advanced analytics and predictive AI company announced that the Institute for Systems Biology (ISB) will employ Virtualitics' AI platform to enable researchers to discover the connections between vast amounts of Covid-related data for a research study on Long Covid treatment options.
  • The research builds on a recent Long Covid study by ISB published in the journal Cell that uncovered four risk factors, measured before or at COVID-19 diagnosis, that identify which patients are likely to develop Long Covid.
  • Virtualitics' patented visualizations makes advanced analytics accessible to non-data scientists and enables researchers to explore their research directly.
  • "The Virtualitics AI Platform accelerates product development for life sciences organizations," said Ciro Donalek, CSO and cofounder of Virtualitics.

Virtualitics launches AI platform to bring trust, speed, and ease to AI-driven decisions

Retrieved on: 
Wednesday, March 16, 2022
Government, Decision-making, Trust, Organization, AI, Business, Research, CEO, NASA, Jet Propulsion Laboratory, Workflow, Technology, California Institute for Quantitative Biosciences, Medical device, Milk

PASADENA, Calif., March 16, 2022 /PRNewswire/ -- Today, Virtualitics Inc, an advanced analytics and predictive AI company, announced the launch of the  Virtualitics AI Platform that aims to help enterprises and government agencies make reliable business decisions, faster with ready-to-use AI that can be understood–and used–by analysts and business stakeholders alike.

Key Points: 
  • Virtualitics' End-to-End AI Platform allows companies to simplify the process of embedding AI into the flow of everyday decision making.
  • Virtualitics launches AI platform to bring trust, speed, and ease to AI-driven decisions.
  • The Virtualitics AI Platform supports the full end-to-end AI workflow and makes it easy for businesses to embed in their operations and take action.
  • Virtualitics AI Platform solves this problem by making AI both understandable and accessible to anyone in the business."